Abstract
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease in which 30% of patients are seronegative for the two serological RA markers, rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (ACCP). However, both markers also have lower sensitivities in early stages of the disease. The lack of effective biomarkers for this subpopulation of RA patients causes a delayed diagnosis. Therefore, discovery of novel circulating autoantibody biomarkers for these early RF-negative and ACCP-negative RA patients are advance planning of these subsets. 136 enriched antigenic markers were identified by high-throughput screening an RA library with autoantibodies in the sera of RA patients (positive selection) and healthy control (negative selection). Phage-ELISA-based re-screening determined 13 out of 136 enriched antigenic targets in which increased antibody levels rised up. Two of the 13 identified targets, namely special A-T rich DNA binding protein (SATB1) and EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1), which had highest increased antibody levels, were selected for further characterization. Reactivity of serum antibodies against these proteins was tested in a protein ELISA using the sera of 137 RA patients and 159 healthy controls. Autoantibodies against SATB1 were detected with 79% sensitivity and 82% specificity, while 87% sensitivity and 52% specificity were obatained for antibodies directed against EFEMP1. With regard to cytokine assay, interestingly, pro-inflammationary cytokines including TNF (tumour necrosis factor) increased over 1000 pg/ml or IL-4 (interleukin-4) or IL- 13 similarly increased up to 90 pg/ml and 102 pg/ml, respectively for co-culture with anti-SATB1 monoclonal antibody. Under treatment with EFEMP1 mAb resulting IL-1, TNF and IL-4 triggered up to 1300 pg/ml, 1250 pg/ml and 180 pg/ml, respectively. In T cell phenotype characterization, two subsets of CD4 + T cell and CD8 + cell were stimulated and differentiated from peripheral blood mononuclear cells (PBMCs) at 29.7% and 1.2% for anti-SATB mAb; 31.3% and 2.8% for anti-EFEMP1 mAb.
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 IFMBE
About this paper
Cite this paper
Nguyen-Hung, A., Le-Thanh, B., Govart, C., Somers, V., Nguyen-Hong, S. (2013). Identification and Characterization of Novel Autoantibody Biomarkers for Rheumatoid Factor-Negative and Accp-Negative Rheumatoid Arthritis. In: Toi, V., Toan, N., Dang Khoa, T., Lien Phuong, T. (eds) 4th International Conference on Biomedical Engineering in Vietnam. IFMBE Proceedings, vol 49. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-32183-2_22
Download citation
DOI: https://doi.org/10.1007/978-3-642-32183-2_22
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-32182-5
Online ISBN: 978-3-642-32183-2
eBook Packages: EngineeringEngineering (R0)